Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Breathes Easy: FDA Approves Exubera

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.

Related Content

Pfizer’s Exubera Receives Nicer Recommendations From U.K.’s NICE
Lilly/Amylin Look To Limit Byetta Access Due To Cartridge Shortage
Pfizer’s Exubera Launch Now Slated For July
Waiting to Exhale: Lilly Inhaled Insulin NDA Filing Will Wait For Safety Data
Novo Nordisk Inhaled Insulin To Resume Phase III Studies
Lilly Begins Efficacy Study For Inhaled Insulin
Exubera Adoption Not Recommended By U.K. Cost-Effectiveness Group
Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors
Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
Exubera Approved In Europe One Day Before U.S. User Fee Date





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts